Global immunology market to grow by $65.8b by 2028

It is driven by advancements in organ transplantation and a strong pipeline of immunological agents.

The global immunology market is expected to grow by $65.8b from 2024 to 2028, with a compound annual growth rate (CAGR) of 9.45%, according to Technavio. 

The growth is driven by advancements in organ transplantation and a strong pipeline of immunological agents. However, the rise of biosimilars presents challenges to market growth.

As of October 2021, 51 molecules are in development, with 22 in Phase II trials and four in Phase III. 

The increasing prevalence of infections and cancers is also driving demand for systemic medications, including interleukin-6 inhibitors and DMARDs. 

The report noted that pharmacists are essential in managing drug schedules. Innovative therapies and targeted immunotherapies, such as Rituximab and Adalimumab, are also changing the treatment landscape, especially for cancer and allergies.